

Faculty/Planning Committee Disclosure Index

ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenter disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where they exist. Financial relationships reported by members of ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee are also provided below. During all phases of planning for the Meeting, areas of conflict were managed through a peer-review process and/or through individual recusal when appropriate. Faculty who are also Planning Committee members are indicated with a cross (†). Faculty/Planning Committee members with no significant relationships to disclose are indicated with an asterisk (*). M - Myself, I - Immediate Family Member, B - Myself and Immediate Family, C - Compensated, U - Uncompensated

Faculty	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Abrams, Jeffrey S.*†							
Baselga, Jose		Merck; Novartis; Roche; Exelixis		GlaxoSmithKline	GlaxoSmithKline		
Batchelor, Tracy T.		Enzon Corporation		Schering-Plough	Millennium; AstraZeneca		
Birrer, Micahel J.*†							
Clark, Gary M.	OSI Pharmaceuticals, Inc.		OSI Pharmaceuticals, Inc.				
Dancey, Janet E.*†							
de Bono, Johann S.					Immunicon trial IMMC38		
Dobbin, Kevin*†							
George, Daniel J.		Wyeth; sanofi-aventis; Pfizer; GlaxoSmithKline; GE Healthcare; Abbott; Bayer		Pfizer; sanofi-aventis	Veridex; Novartis; Pfizer; NIH; Amgen; Dendreon; DOD; GlaxoSmithKline		
Grandis, Jennifer R.*							
Harbeck, Nadia†		Roche Diagnostics					
Hegi, Monika†		Merck-Serono; Oncomethylome Sciences		Schering Plough	AstraZeneca		
Heymach, John		Pfizer; Genentech; AstraZeneca; GlaxoSmithKline			Pfizer; AstraZeneca; GlaxoSmithKline		
Hilsenbeck, Susan G.*†							
Hochhaus, Andreas		Novartis		Novartis, Bristol-Myers Squibb	Novartis, Bristol-Myers Squibb, Wyeth, MSD, Roche, Innovive		
Innocenti, Federico							Royalties from the commercialization of the UGT1A1 genetic test
Jain, Rakesh K.*							

FACULTY DISCLOSURE INDEX

Faculty	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Janne, Pasi A.		Boehringer Ingelheim; Astra Zeneca; Roche; AVEO Pharmaceuticals			Pfizer		Genzyme
Jessup, J. Mulburn*†							
Johnson, Bruce E.†		Genzyme					Royalty payments on a license to Genzyme for doing EGFR mutation testing
Lively, Tracy G.*†							
Lusa, Lara*							
Müller, Volkmar*							
Pantel, Klaus*							
Pirker, Robert		Merck KGaA		Merck KGaA			
Rini, Brian I.		Wyeth; Pfizer; Genentech; Novartis			Wyeth; Pfizer		
Schilsky, Richard L.		Novartis Oncology - Member, Data Monitoring Committee; AdventRx Pharmaceuticals - Member, Data Monitoring Committee (Compensation within last two years but prior to becoming Pres-Elect)					
Sequist, Lecia V.*							
Shankar, Lalitha*†							
Small, Eric J.†		Cougar Pharmaceuticals; Poniard Pharmaceuticals; Amgen			Cell Genesys; Dendreon Pharmaceuticals		
Sotiriou, Christos*†							
Stearns, Vered†		Wyeth			Pfizer; GlaxoSmithKline; Novartis		
Stroobants, Sigrid*†							

Faculty	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Stupp, Roger†		Antisense Pharma, Regensburg, Germany; Bradmer Pharmaceuticals, Inc, Louisville, KY; Merck KGaA, Darmstadt, Germany	Pfizer	Schering-Plough, Kenilworth, NJ			
Sweep, Fred C.*†							
Thor, Ann*†							
Van Cutsem, Eric		Amgen (M, U); Pfizer (M, U); Merck-Serono (M, U); Roche (I, U); sanofi-aventis (M, U); Novartis (M, U)			Novartis (M); Merck-Serono (M); Amgen (M); Roche (M); sanofi-aventis (M); Pfizer (M)		
Weber, Wolfgang A.*							